Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Takeda IMS Company Profile' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Takeda IMS Company Profile |
September 2009 | £510 | 100 % |
|
Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile |
February 2009 | £1990 | 49.5 % |
|
Millennium Pharmaceuticals SWOT Analysis |
November 2008 | £44 | 44 % |
|
Millennium Pharmaceuticals, Inc. - SWOT Analysis |
November 2008 | £44 | 40 % |
|
Takeda: Pipeline, Products,Performance,Potential |
November 2009 | £595 | 38.5 % |
|
Takeda Pharmaceutical Company Limited - SWOT Analysis |
January 2009 | £44 | 35 % |
|
Schering-Plough Corporation Deals Partneringdesk briefing |
July 2005 | £215 | 23.5 % |
|
Takeda Pharmaceutical Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 22.4 % |
|
Tanabe Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 | 21.5 % |
|
The Top 50 Pharmaceutical Manufacturing Companies In Ireland |
September 2005 | £300 | 21.5 % |
|
Takeda Pharmaceutical Co., Ltd Pharmavitae Profile |
December 2007 | £1990 | 18.2 % |
|
The Japanese Pharmaceutical Market Outlook to 2014 Policy environment, market structure, competitive landscape, growth opportunities |
January 2010 | £3835 | 18 % |
|
Partnering Agreements with Takeda 2010 |
January 2010 | £295 | 17.85 % |
|
NRT Smoking Cessation Aids in Japan |
June 2006 | £450 | 14 % |
|
Diabetes Market Forecast to 2015 |
January 2010 | £6600 | 14 % |
|
Mergers and Aquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £995 | 13.3 % |
|
Mergers and Acquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £1955 | 13.3 % |
|
Eye Care in Japan |
September 2007 | £450 | 10.5 % |
|
Medicated Skin Care in Japan |
September 2007 | £450 | 10.5 % |
|
Obesity Drug Discoveries: what the future holds |
August 2007 | £1425 | 10.5 % |
|
Bigpharma Dealmaking Handbook Companies & Contacts |
September 2008 | £1195 | 8.4 % |
|
Bigpharma Dealmaking and Agreements Handbook 2007 Companies, Contacts & Partnering Agreements |
September 2007 | £1195 | 7.7 % |
|
Partnering Agreements with Bigpharma |
February 2010 | £1395 | 7 % |
|
Global Diabetes Market; The Therapeutics, Diagnostics and Complications |
August 2006 | £1650 | 6.65 % |
|
Johnson & Johnson: PharmaVitae Profile Healthcare |
July 2009 | £3765 | 6.3 % |
|
Johnson & Johnson PharmaVitae Profile |
July 2008 | £1980 | 5.95 % |
|
Commercial Insight: Antihormonal Therapy Cancer Brands Careful Lifecycle Management Needed to Preserve Brand Dominance |
August 2008 | £5020 | 5.6 % |
|
Astellas Pharma Inc.: PharmaVitae Profile |
February 2009 | £1990 | 4.9 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1745 | 4.2 % |
|
Commercial Insight: Antidiabetics in Australia Reimbursement status shapes novel classes |
October 2009 | £3765 | 4.2 % |
|
Lymphoma Drug Development Strategies at Work |
June 2009 | £1745 | 3.85 % |
|
Monoclonal Antibody Therapeutics 2009-2024 |
August 2009 | £1499 | 3.85 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £3965 | 3.5 % |
|
World Gastrointestinal Disorders Market 2008-2023 |
October 2008 | £1499 | 3.5 % |
|
Competitive Outlook of Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
August 2009 | £2195 | 3.5 % |
|
Anti-Hypertensive Drugs |
February 2010 | £2610 | 3.15 % |
|
CNS Drug Discoveries What the Future Holds |
November 2006 | £1995 | 3.15 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £5285 | 2.45 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £3205 | 2.1 % |
|
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries |
July 2007 | £5020 | 2.1 % |
|
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit |
July 2007 | £3965 | 2.1 % |
